Decitabine

製品コードS1200 別名:Deoxycytidine

Decitabine化学構造

分子量(MW):228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

サイズ 価格(税別)  
JPY 25730.00
JPY 14940.00
JPY 28220.00
JPY 53120.00
JPY 94620.00

カスタマーフィードバック(3)

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 NXr6elQ5TnWwY4Tpc44hSXO|YYm= MoTVNE42yqEQvF2= NUPlTYxUOjRiaB?= MX73ZZRmeg>? M2W2UY1w\HWuYYTld{B1cGViZ3Xu[UBmgHC{ZYPzbY9vKG:oIF3BS2UuSSCvZX3i[ZJ{ NWjjbYRIOjVzMkOwPFI>
Eca109 NHnWV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXqwMlUwOi53L{Wg{txO NVTpflRQOjRxNEivO|IhcA>? MV33ZZRmeg>? MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLTDk[ZBmdmSnboSgcYFvdmW{ M{e2U|I2OTJ|MEiy
Eca109 MmjxSpVv[3Srb36gRZN{[Xl? MmSyNE42yqEQvF2= M4D2WlYwOTJxMkSgbC=> Mom5e4F1\XJ? MV7pcohq[mm2czDj[YxtKG2rZ4LheIlwdsLi NVP6bJRIOjVzMkOwPFI>
Eca109 NFjXOHlHfW6ldHnvckBCe3OjeR?= M1PBPVAvPcLizszN MY[yOEBp MXv3ZZRmeg>? MVHpcohq[mm2czDj[YxtKGmwdnHzbY9v M1HQPFI2OTJ|MEiy
Eca109 NH\WepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTDNE42yqEQvF2= MY[yOEBp NF;nOlF4[XSnch?= MlXibY5lfWOnczDHNk9OKGG{cnXzeEBqdiC2aHWgZ4VtdCCleXPs[S=> M4SzdlI2OTJ|MEiy
Eca109 MonKSpVv[3Srb36gRZN{[Xl? M1\2elAvPS9zIN88US=> MmDhNlQhcA>? NWrh[JBFf2G2ZYK= MWDk[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz MW[yOVEzOzB6Mh?=
SW1116  MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr1NE42NzFxMj:1JO69VQ>? NHj4[|U1QCCq M4PUTWROW09? MkPK[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> NXrGdXRwOjR6N{SyPFY>
LOVO M2jZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTwcJcxNjVxMT:yM|Uh|ryP NEjXWmc1QCCq NFqy[2tFVVOR M2q4WYVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44> MnLJNlQ5PzR{OE[=
SW1116  MnfLSpVv[3Srb36gRZN{[Xl? NVyzdIFGOTBizszN MonYOFghcA>? MWLEUXNQ MV7pcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> NXiyPIRCOjR6N{SyPFY>
LOVO M4nvRWZ2dmO2aX;uJGF{e2G7 MorxNVAh|ryP NHW0fIU1QCCq NXPmWFRsTE2VTx?= M13mc4lv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? NIe0emwzPDh5NEK4Oi=>
SW1116  MkG2RZBweHSxc3nzJGF{e2G7 NV7uU4diOTBizszN MYq0PEBp NWrVRldrTE2VTx?= NIX3XnRmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> NYP0R4lZOjR6N{SyPFY>
LOVO M{jid2Fxd3C2b4Ppd{BCe3OjeR?= NU[4S|hmOTBizszN M3HyNVQ5KGh? M1zRSmROW09? M4LLToVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> MWeyOFg4PDJ6Nh?=
RPMI-8226 NFOyeFFCeG:ydH;zbZMhSXO|YYm= NFvrOFgyNzJizszN MUe0PE84Oi97NjDo MWTEUXNQ NFLRO|RqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3L2dVI1QDN|MUC4
OPM-2  Ml:zRZBweHSxc3nzJGF{e2G7 MWCxM|Ih|ryP M1LTTlczNzl4L{GyNEBp NVTXXpd5TE2VTx?= NIXRe|BqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MmPmNlQ5OzNzMEi=
JJN3  NUTlUHl7SXCxcITvd4l{KEG|c3H5 M4P0TlAvPS9zIN88US=> MYGyOE81QCCq MUPEUXNQ M2fRfolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M2HoR|I1QDN|MUC4
NCI-H929  M3\meWFxd3C2b4Ppd{BCe3OjeR?= MVexM|Ih|ryP MX:3Nk86Pi9zMkCgbC=> NYDYPHNJTE2VTx?= NWLxToZPcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NHLTWoMzPDh|M{GwPC=>
RPMI-8226 M4T1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWixM|Ih|ryP NFHYfIozPC92OD:3NkBp M1nOV2ROW09? Mnn5ZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? MkLoNlQ5OzNzMEi=
OPM-2  MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PPbFEwOiEQvF2= Mmi2NlQwPDhxN{KgbC=> NGKxbmtFVVOR NGiyfnJi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MlrJNlQ5OzNzMEi=
JJN3  NWDCZ4dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfIdGtXOC53L{Gg{txO MYeyOE81QC95MjDo MX7EUXNQ Mn;2ZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? Mmi3NlQ5OzNzMEi=
NCI-H929  M{P6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrqcHUyNzJizszN NFTzN3ozPC92OD:3NkBp MnH3SG1UVw>? Moe2ZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? MkX6NlQ5OzNzMEi=
HeLa NE\iNFZMcW6jc3WgRZN{[Xl? NHnDOYdMcT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy NVHY[Y5NOjR5OECwPVg>
HeLa NWfrSGNiU2mwYYPlJGF{e2G7 MnThT4k:PS54INMxJFAvPSEQvF2g[o9zKGiHTmSy M{T3ZlI1PzhyMEm4
HeLa MVTLbY5ie2ViQYPzZZk> MXnLbV0zOS54INMxJFMvOCEQvF2g[o9zKGiFTmSx NUHZNIJxOjR5OECwPVg>
HeLa NIHJ[opMcW6jc3WgRZN{[Xl? Moi1T4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=> NV7tdXI2OjR5OECwPVg>
NB4 M4L1TGZ2dmO2aX;uJGF{e2G7 MVWyMlUwPS95LkWvNVAh|ryP NWrhSIFGOjRiaB?= MkTISG1UVw>? M1\Ee4lv[3KnYYPlZUB1cGViZYjwdoV{e2mxbjDv[kBxemWldYLzc5IhdWmULUGyOYE> MU[yOFQ5PDh5MB?=
CD4+ CD25− T  NYPYc3RkTnWwY4Tpc44hSXO|YYm= M1\aR|EwPSEQvF2= MlTjdoVlfWOnUzDncI9j[WxiRF7BJI1mfGi7bHH0bY9v MYKyOFQ4PjN4MB?=
BV-173 NHTxcIpCeG:ydH;zbZMhSXO|YYm= MXOwMlI2NzBwNT:wMlc2NzFizszN M{H1fFQ5Nzd{L{m2JIg> MV|CpHBDWw>? MVzpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NV7yS5FVOjR2MkO2NVM>
ML-1 NH;ucFJCeG:ydH;zbZMhSXO|YYm= NGfXNHQxNjJ3L{CuOU8xNjd3L{Gg{txO NEjLZYk1QC95Mj:5OkBp NF7GRpfDqFCEUx?= MWTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= M1;ObFI1PDJ|NkGz
HL-60 M{TQU2Fxd3C2b4Ppd{BCe3OjeR?= MVuwMlI2NzBwNT:wMlc2NzFizszN NVjpZ2VRPDhxN{KvPVYhcA>? MXpCpHBDWw>? NYjwc|JIcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz Ml3WNlQ1OjN4MUO=
KG-1a MU\BdI9xfG:|aYOgRZN{[Xl? NWrCWJE{OC5{NT:wMlUwOC55NT:xJO69VQ>? NVrnSFJvPDhxN{KvPVYhcA>? NUnPcpNKyqCSQmO= NVHm[XhWcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MXKyOFQzOzZzMx?=
BV-173 NFfTdndHfW6ldHnvckBCe3OjeR?= MVuyOVAwPTBybl2= NEfMUVI1QCCq MmnMxsBRSlN? MnnzbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NUTOenV5OjR2MkO2NVM>
CEM NVHibYNDTnWwY4Tpc44hSXO|YYm= NHL0UogzPTBxNUCwcm0> MkPZOFghcA>? NF[0VnbDqFCEUx?= M2rCT4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= M2XzTFI1PDJ|NkGz
HL-60 NEm0UZBHfW6ldHnvckBCe3OjeR?= NED3WYQzPTBxNUCwcm0> MWO0PEBp NVnjOJYzyqCSQmO= M1TKZYlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NInSfnYzPDR{M{[xNy=>
ML-1 NXjPbYZVTnWwY4Tpc44hSXO|YYm= MmLmNlUxNzVyMH7N M2qwTlQ5KGh? NF\pfonDqFCEUx?= MV3pcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NF3kbGYzPDR{M{[xNy=>
DLD-1 NIjYUlNHfW6ldHnvckBCe3OjeR?= M2\ueVI2OC93MEDuUS=> MXy0PEBp NFPJPGrDqFCEUx?= MlL4[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? MVqyOFQzOzZzMx?=
HCT-116 MVvGeY5kfGmxbjDBd5NigQ>? NFfMdnczPTBxNUCwcm0> NIPxNI81QCCq NXHwSIhFyqCSQmO= NWL4NpFr\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= M2Pa[FI1PDJ|NkGz
U937-A/E-9/14/18  NFvvOpBCeG:ydH;zbZMhSXO|YYm= M3jNXFAvODFxMD6xM|EwOTBizszN NHrYdWY1QCCq NHr3S4VqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXfaVIRsOjR|MEC0OVY>
HT29 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkntO|IhcA>? NVrzXVZLUUN3ME2xOFAxyrFzN{mg{txO NFXFfIMzPDF5MkC2NS=>
SW48 M3rxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;ZbZA4OiCq NU\sW|RMUUN3ME2xOU4zyrF4LkKg{txO MV6yOFE4OjB4MR?=
HCT116 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vId|czKGh? NVTHXlJ1UUN3ME2xMlfDuTBwNDFOwG0> NXf2VGxqOjRzN{KwOlE>
HepG2 M2SzUWZ2dmO2aX;uJGF{e2G7 NXHvcXN{OC53L{Gg{txO MX6yOEBp NYnF[2s3TE2VTx?= NU\qflV1fXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= MYeyOFE1Pjh5NB?=
LS174T MU\GeY5kfGmxbjDBd5NigQ>? MkTGNE42NzFizszN NE\M[3kzPCCq M2XxVGROW09? MnWxcIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO= MnfqNlQyPDZ6N{S=
HepG2 MVjBdI9xfG:|aYOgRZN{[Xl? MkDGNU8yOC9zMECg{txO NVTOdHFuPyCm M4XtVGROW09? M4PiXolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIPneWczPDF2Nki3OC=>
LS174T MV\BdI9xfG:|aYOgRZN{[Xl? NGTnV3IyNzFyL{GwNEDPxE1? Mn[0O{Bl MlfqSG1UVw>? MUjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVyyOFE1Pjh5NB?=
QBC-939 M{XTXmFxd3C2b4Ppd{BCe3OjeR?= M{SzdFEwOTBxMUCwJO69VQ>? NIO0SXo4KGR? Mme4SG1UVw>? NH;abJlqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NY\wVY9vOjRzNE[4O|Q>
U251 M4P4OGFxd3C2b4Ppd{BCe3OjeR?= NE\PRlYyNzFyL{GwNEDPxE1? M3PPcFch\A>? MoLkSG1UVw>? MnrJbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVn5RmhvOjRzNE[4O|Q>
HL-60 NX7OZoROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX62cmpOOSEQvF2= NGCxTFA1QCCq MoXsbY5kemWjc3XzJGczNXCqYYPlJINmdGxiZoLhZ5Rqd25? MXKyOFAxODN{NB?=
MDA‑MB‑453 M2fBVWZ2dmO2aX;uJGF{e2G7 MmeyNE4zNzFizszN MV63NkBp NUOxb5Fy[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh NXrhVpVVOjN6NESyNlg>
HCC1569 NInpWJJHfW6ldHnvckBCe3OjeR?= Mm\KNE4zNzFizszN M2XmbFczKGh? M4nZNINifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> NUXXRmxFOjN6NESyNlg>
BT‑474 NIfPb5BHfW6ldHnvckBCe3OjeR?= NGnoTo4xNjJxMTFOwG0> M1nKcVczKGh? Mlr6Z4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg MVqyN|g1PDJ{OB?=
AGS MkfvRZBweHSxc3nzJGF{e2G7 NYfMflhjPS9zMD:yNE82OCEQvF2= NFPiO3c1QMLiaNMg NYXD[GlVTE2VTx?= M2rBdIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh NFLzcpAzOzV6Mke4OC=>
A549 MnTyRZBweHSxc3nzJGF{e2G7 Mni3OU8yOC9{MD:1NEDPxE1? M3yydlQ5yqCqwrC= MkjlSG1UVw>? M4PJWYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh NUKySHd[OjN3OEK3PFQ>
AGS  Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDJOU8yOC9{MD:1NEDPxE1? MWC0POKhcMLi MVjEUXNQ M{H5e4lv\HWlZYOgS|IwVSCyaHHz[UBienKnc4VCpC=> NE\UOG4zOzV6Mke4OC=>
Kasumi-1 MkOzRZBweHSxc3nzJGF{e2G7 NUf2WJF5OC53IN88US=> M2TTe|Q5yqCqwrC= Mk\W[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NWroRmR2OjN2OUOzOFg>
OCI-AML3 MVnBdI9xfG:|aYOgRZN{[Xl? MWWyMlUh|ryP Mn;MOFjDqGkEoB?= NXfkeJdj\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> MkTtNlM1QTN|NEi=
MV4-11 Mn;FRZBweHSxc3nzJGF{e2G7 MYWyMlUh|ryP MljYOFjDqGkEoB?= MU\k[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= M1zsS|I{PDl|M{S4
NK  NXvi[ZFyS3m2b4TvfIl1gSCDc4PhfS=> NV\mUXg6OC5yMj2yNEDPxE1? NIW3U|A2KGR? Mmrt[IVkemWjc3XzJJRp\SCleYTvcJl1cWNiYXP0bZZqfHlib3[gUmsh[2WubIOgZZQhcW62ZYLt[YRq[XSnIHPvcoNmdnS{YYTpc45{KHKnc4XseIlv\yCrbjDhJHUue2ijcHXkJIRwe2YkgKPy[ZNxd26|ZTDjeZJ3\Q>? NHG0SHIzOzN{OEC4PC=>
NK  MoSzRZBweHSxc3nzJGF{e2G7 NWiyfII6OC5yMj2yNEDPxE1? Mn60OUBl NFfqbnFl\WO{ZXHz[UBPUyClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fUBieyC2aHWgZ49v[2WwdILheIlwdiCrbnPy[YF{\WR? NVrlXGdWOjN|MkiwPFg>
NK  NX:2d|dyTnWwY4Tpc44hSXO|YYm= NULNN2l1OC5yMT2yNEDPxE1? MVq1JIQ> MYTjZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy|IHnuJIEh\G:|ZfMAl5Jme3CxboPl M3fyU|I{OzJ6MEi4
MOLT4/DNR MkXqSpVv[3Srb36gRZN{[Xl? NHnQO2Y2KM7:TR?= MljPOEBl MWfy[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> NGrjS5kzOzB4MEW3NC=>
Jurkat/DOX NFr6W4ZHfW6ldHnvckBCe3OjeR?= NEDHd|Q2KM7:TR?= MX60JIQ> MnjodoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> MVmyN|A3ODV5MB?=
MOLT4/DNR NVPMZm95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWC1JO69VQ>? NGq0dpE1KGR? MXzy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 MkC2NlMxPjB3N{C=
Jurkat/DOX MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrYVoR5PSEQvF2= M3;KOlQh\A>? MV7y[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 M3zQSVI{ODZyNUew
ccRCC  NHrjUWZCeG:ydH;zbZMhSXO|YYm= M4rRTVAvODFvMUFOwG0> NFzYeZY4OiCq MlXXSG1UVw>? Ml[0bIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? MX6yNlgzPjR4Nx?=
TNBC  M125e2Fxd3C2b4Ppd{BCe3OjeR?= M4X5T|AvODFvMUFOwG0> MXm3NkBp NIPKcYFFVVOR MonzbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? MXyyNlgzPjR4Nx?=
A498 M4LEZmFxd3C2b4Ppd{BCe3OjeR?= NIXXOIkxNjBzLUGw{txO MXu3NkBp NWDFRWVNTE2VTx?= MmfFbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NHHvW28zOjh{NkS2Oy=>
KIJ265T NEHIcJNCeG:ydH;zbZMhSXO|YYm= MlXhNE4xOS1zMN88US=> M2HBWFczKGh? M3vSbGROW09? NUG4fWVKcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? MlnZNlI5OjZ2Nke=
MDA-231 NH;OTWZCeG:ydH;zbZMhSXO|YYm= NUC4cWZrOC5yMT2xNO69VQ>? NFjaN5Y4OiCq MWDEUXNQ NGjNOI1qdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NWD2cnBCOjJ6Mk[0Olc>
BT-20 NGTPN4hCeG:ydH;zbZMhSXO|YYm= NX\xUGdxOC5yMT2xNO69VQ>? NEjNSIw4OiCq M{\KbGROW09? MXTpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu M1;YcVIzQDJ4NE[3
U937 M1vEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3QTJZEPS1{MDFOwG0> Mm\4NlQwPDhxN{KgbC=> M1v5bolv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MoPQNlI4PjdyMkG=
HL60 NFjHUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvpOU0zOCEQvF2= NXTlV|N6OjRxNEivO|IhcA>? NX\De5AycW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M{nYdFIzPzZ5MEKx
U937 MkG0RZBweHSxc3nzJGF{e2G7 NFfxT4wyPSEQvF2= MnPkNlQwPDhxN{KgbC=> MVvpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MlT1NlI4PjdyMkG=
HL60 MV3BdI9xfG:|aYOgRZN{[Xl? NWXSWnd4OTVizszN MYWyOE81QC95MjDo MnvVbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MoW3NlI4PjdyMkG=
LS411N  MVTBdI9xfG:|aYOgRZN{[Xl? NVnmVZhDOC53IN88US=> MWS3NkBp M4G0N4lv[3KnYYPld{BH[XNibWLORUBt\X[nbB?= NWDLdGN1OjJ2NkG2PVU>
MDA-MB-231 M1PJVmFxd3C2b4Ppd{BCe3OjeR?= M{PXfFExKM7:TR?= NVjrXWFvPDhiaB?= MUfy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkThNlE5QDd4OUe=
MCF-7  M3Tyb2Fxd3C2b4Ppd{BCe3OjeR?= NVjBTFNKOTBizszN Mm\hOFghcA>? Ml:zdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWTneZIzOjF6OEe2PVc>
A375 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17SWVAvPSEQvF2= M2XmNVEwPS96IHS= NFHJZ2JqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NH\pRpozOTd7Nk[yNi=>
SKMEL1 NU[5[4YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrIS4cxNjVizszN MnvONU82NzhiZB?= M4XhU4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| M1q1UlIyPzl4NkKy
SKMEL3 NHTmd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnPfW8{OC53IN88US=> MoD6NU82NzhiZB?= MlTlbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NYLKUHpiOjF5OU[2NlI>
SKMEL28 NXXp[lYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjNc5BMOC53IN88US=> MUKxM|UwQCCm MnzzbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? Mnf1NlE4QTZ4MkK=
MeWo NVnw[nAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\DWVAvPSEQvF2= Ml\ENU82NzhiZB?= Mlz1bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NWPvWndlOjF5OU[2NlI>
B16 NF;2dINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDxNE42KM7:TR?= MljXNU82NzhiZB?= MkH3bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NHfnSXYzOTd7Nk[yNi=>
Ly 1 NWLEN2E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVniZYhZOjRiaB?= M3\6O2lEPTB;Nz6zJO69VQ>? MUSyNVc4OjB2OR?=
Ly 7 NGrGbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e1O|I1KGh? NXn2TFQzUUN3ME2xNE44KM7:TR?= NVX2VnI5OjF5N{KwOFk>
Su-DHL6 M{G3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnxcW0zPCCq NX3mTZJkUUN3MP-8olIxKM7:TR?= NEfleZIzOTd5MkC0PS=>
Ly 10 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW3R|IzPCCq NG\ZSXlKSzVy78{eNlAh|ryP MlnkNlE4PzJyNEm=
RIVA MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfkZ24zPCCq M2Lz[GlEPTExvK6yNEDPxE1? NGXQNIMzOTd5MkC0PS=>
Su-DHL2 Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;vTYMzPCCq M4rXVWlEPTExvK6yNEDPxE1? MUSyNVc4OjB2OR?=
Ly 1 M4jodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fy[|Q5KGh? NWixRoxRUUN3ME2wMlM1KM7:TR?= MmnnNlE4PzJyNEm=
Ly 7 M3rwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYG0PEBp NFjWOpdKSzVyPUCuNFI2KM7:TR?= NHruWnIzOTd5MkC0PS=>
Su-DHL6 NF;KV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfIUVlHPDhiaB?= M4HrfGlEPTExvK6yNEDPxE1? M1XrTVIyPzd{MES5
Ly 10 NU\tOW13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXS0PEBp MUnJR|UxRTFwODFOwG0> NFX0bFMzOTd5MkC0PS=>
RIVA NVjPRpZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvOVlhlPDhiaB?= NXPkXFFJUUN3MP-8olIxKM7:TR?= NGizOnEzOTd5MkC0PS=>
Su-DHL2 MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTWV45LPDhiaB?= Mn:1TWM2OD1zNz60JO69VQ>? NIfGWnQzOTd5MkC0PS=>
Ly 1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYi3NkBp NITHUnRKSzVyPUCuNFEh|ryP NVrRXIFzOjF5N{KwOFk>
Ly 7 M{TE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULDfnhiPzJiaB?= NEi5epRKSzVyPUCuNFE5KM7:TR?= NXLiW3ZFOjF5N{KwOFk>
Su-DHL6 NXf5ToNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnToO|IhcA>? M{HBVmlEPTB;MT62JO69VQ>? NHz0[lIzOTd5MkC0PS=>
Ly 10 NYrGNnYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVG3NkBp M{LxVmlEPTB;MT6yJO69VQ>? Mk\wNlE4PzJyNEm=
RIVA MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfYVFE4OiCq NHTxPYVKSzVy78{eNlAh|ryP NHzPcWgzOTd5MkC0PS=>
Su-DHL2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:0W|czKGh? MYfJR|UxRTFzLkKg{txO M2W3VlIyPzd{MES5

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
+ 展開
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 製剤: Decitabine is dissolved in sterile PBS .
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管
in solvent
別名 Deoxycytidine

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferaseシグナル伝達経路

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID